Pharmacokinetics of diacerein in patients with liver cirrhosis

✍ Scribed by O. Magnard; K. Louchahi; M. Tod; O. Petitjean; P. Molinier; L. Berdah; G. Perret

• Publisher: John Wiley and Sons
• Year: 1993
• Tongue: English
• Weight: 388 KB
• Volume: 14
• Category: Article
• ISSN: 0142-2782
• DOI: 10.1002/bdd.2510140506

✦ Synopsis

The pharmacokinetics of diacerein following a single oral dose of 50 mg was studied in 12 healthy volunteers, 10 patients with a mild liver cirrhosis (Child Pugh's grade A), and 6 patients with a more severe liver cirrhosis (Child Pugh's grade B to C). Statistical analysis using a Kruskal-Wallis test showed no significant differences between the three groups for the following parameters: median C , , was 3.9mgl-' for the cirrhotic patients group I (CPI) and 3 a2 mg 1-' for the cirrhotic patients group I1 (CPII) versus 3-2 mg 1-' for the healthy volunteers (HV); median t , was 4.9 h for CPI and 4 -3 h for CPII versus 4.3 h for HV; median Cl/F was 2.1 1 h-' for CPI and 2.5 1 h-' for CPII versus 1.6 1 h-' for HV; median Vdss/F was 12.6 1 for CPI and 14.0 1 for CPII versus 13.21 for HV. The urinary parameters were comparable. It was concluded that, from a pharmacokinetic point of view, no reduction in the initial dosage of diacerein need be proposed in liver cirrhosis.